Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:54:09 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Z:PFE - PFIZER INC - http://www.pfizer.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PFE - Z0.125.35·25.381.225.39-0.035-0.135,782.2899,69584,26125.35  25.46  25.2340.56  25.2619:59:39Apr 1115 min RT 2¢

Recent Trades - Last 10 of 84261
Time ETExPriceChangeVolume
19:59:39Z25.3599-0.06015
19:59:35Z25.36-0.0615
19:59:10Z25.365-0.0551
19:58:37Z25.3699-0.05015
19:58:04Z25.37-0.055
19:58:04Z25.37-0.0536
19:57:51Z25.385-0.0351
19:57:25Z25.37-0.051
19:57:25Z25.38-0.041
19:57:17Z25.38-0.041

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-11 10:00U:PFENews ReleasePfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
2024-04-09 06:45U:PFENews ReleasePfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO(TM) in Adults Aged 18 to 59 at Increased Risk for RSV Disease
2024-04-08 12:44U:PFENews ReleaseALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
2024-03-20 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
2024-03-13 04:00U:PFENews ReleaseEuropean Commission Approves Pfizer's PREVENAR 20(TM) to Help Protect Infants and Children Against Pneumococcal Disease
2024-03-12 06:45U:PFENews ReleasePfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS(TM) Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2024-03-05 10:00U:PFENews ReleasePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-02-29 17:40U:PFENews ReleasePfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
2024-02-29 08:00U:PFENews ReleasePfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO(TM) for RSV in Older Adults
2024-02-26 10:00U:PFENews ReleasePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-02-19 07:45U:PFENews ReleaseEuropean Commission Approves Pfizer ¢ € ™s VELSIPITY ‚ ® for Patients with Moderately to Severely Active Ulcerative Colitis
2024-02-15 10:00U:PFENews ReleasePfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
2024-02-15 08:45U:PFENews ReleaseGlobal Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
2024-02-14 08:30U:PFENews ReleaseAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
2024-02-14 08:00U:PFENews ReleaseCarrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
2024-02-06 06:45U:PFENews ReleaseArvinas and Pfizer ¢ € ™s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
2024-02-05 10:00U:PFENews ReleaseBreaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
2024-02-02 06:45U:PFENews ReleaseTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
2024-01-30 06:45U:PFENews ReleasePfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
2024-01-26 12:00U:PFENews ReleaseEuropean Medicines Agency Validates Type II Variation Application for PADCEV ‚ ® (enfortumab vedotin) with KEYTRUDA ‚ ® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer